aTyr Pharma (NASDAQ:LIFE) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of aTyr Pharma (NASDAQ:LIFEGet Free Report) in a research report issued on Saturday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Several other brokerages also recently weighed in on LIFE. Royal Bank of Canada reduced their price target on shares of aTyr Pharma from $19.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, March 15th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of aTyr Pharma in a report on Tuesday, May 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $23.67.

Get Our Latest Report on aTyr Pharma

aTyr Pharma Price Performance

Shares of NASDAQ LIFE opened at $1.90 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.07 and a current ratio of 6.07. The company has a 50 day simple moving average of $1.76 and a two-hundred day simple moving average of $1.66. aTyr Pharma has a fifty-two week low of $1.08 and a fifty-two week high of $2.45. The company has a market capitalization of $131.12 million, a price-to-earnings ratio of -2.11 and a beta of 1.19.

aTyr Pharma (NASDAQ:LIFEGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. The company had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.11 million. Analysts expect that aTyr Pharma will post -0.89 EPS for the current fiscal year.

Insider Activity

In related news, CEO Sanjay Shukla purchased 20,000 shares of aTyr Pharma stock in a transaction on Friday, May 31st. The shares were bought at an average cost of $1.81 per share, for a total transaction of $36,200.00. Following the acquisition, the chief executive officer now owns 136,548 shares in the company, valued at approximately $247,151.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Sanjay Shukla purchased 20,000 shares of the business’s stock in a transaction on Friday, May 31st. The stock was acquired at an average price of $1.81 per share, for a total transaction of $36,200.00. Following the acquisition, the chief executive officer now directly owns 136,548 shares of the company’s stock, valued at approximately $247,151.88. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Timothy Coughlin acquired 50,000 shares of the firm’s stock in a transaction dated Thursday, May 30th. The shares were purchased at an average cost of $1.75 per share, for a total transaction of $87,500.00. Following the completion of the acquisition, the director now directly owns 56,000 shares in the company, valued at $98,000. The disclosure for this purchase can be found here. Insiders acquired a total of 75,000 shares of company stock valued at $132,650 in the last 90 days. Company insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On aTyr Pharma

Hedge funds have recently bought and sold shares of the business. Granite Bay Wealth Management LLC purchased a new position in shares of aTyr Pharma in the 4th quarter worth $25,000. Acadian Asset Management LLC lifted its holdings in shares of aTyr Pharma by 119.6% in the 1st quarter. Acadian Asset Management LLC now owns 45,366 shares of the biotechnology company’s stock valued at $87,000 after acquiring an additional 24,704 shares during the last quarter. SG Americas Securities LLC purchased a new position in aTyr Pharma in the first quarter worth about $55,000. Pale Fire Capital SE bought a new stake in aTyr Pharma during the third quarter worth approximately $88,000. Finally, Kingswood Wealth Advisors LLC purchased a new stake in aTyr Pharma during the first quarter valued at approximately $117,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

aTyr Pharma Company Profile

(Get Free Report)

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.

Further Reading

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.